Letairis/Volibris (ambrisentan) - Analysis and Forecasts from 2007 to 2020

Letairis/Volibris (ambrisentan) - Analysis and Forecasts from 2007 to 2020

Summary

GlobalData’s pharmaceuticals report, “Letairis/Volibris (ambrisentan) - Analysis and Forecasts from 2007 to 2020” provides Letairis sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Letairis including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Letairis including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2007-2020 for Letairis in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pulmonary Arterial Hypertension
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology
2.3.1 Scleroderma
2.3.2 Sickle Cell Disease
2.3.3 HIV/AIDS
2.3.4 Drug Abuse and Toxins
2.4 Economic Impact of PAH
2.5 GlobalData Report Guidance
3 Pulmonary Arterial Hypertension (PAH): Market Characterization
3.1 PAH Market
3.2 PAH Market Forecasts and CAGR
3.3 PAH Market : Drivers and Restraints
3.3.1 Drivers
3.3.2 Barriers
4 Classification of PAH
4.1 Classification Based on Cause and Clinical Presentation
4.1.1 Idiopathic PAH
4.1.2 Familial PAH
4.1.3 Drug Induced PAH
4.1.4 PAH Associated with Other Conditions
4.1.5 PAH Associated with Significant Venous or Capillary Involvement
4.2 Symptomatic Profile of PAH
5 Evolution of PAH Treatments
6 Medications
6.1 Prostanoids
6.1.1 Epoprostenol
6.1.2 Treprostinil
6.1.3 Iloprost
6.1.4 Beraprost
6.2 Endothelin Receptor Antagonists
6.2.1 Bosentan
6.2.2 Ambrisentan
6.2.3 Sitaxsentan
6.3 Phosphodiesterase Type 5 Inhibitors
6.3.1 Sildenafil
6.3.2 Tadalafil
6.4 Surgical Treatments
6.5 Investigational Combination Regimens
6.6 New Targets for PAH Therapy
7 Market Share by Class in PAH
8 Letairis/Volibris (ambrisentan)
8.1 Introduction
8.2 Mechanism of Action
8.3 Clinical Studies
8.4 Approval History of Letairis/Volibris
8.5 Factors Affecting Sales of Letairis/Volibris
8.5.1 Better Compliance and Dosing Convenience
8.5.2 Safety and Efficacy Profiles
8.5.3 Cost
8.5.4 Combination Therapy with Tadalafil
8.6 Drug Evaluation
8.6.1 Drug Risk Benefit Score
8.6.2 Intensity of Competition
8.7 Sales Estimates
8.7.1 Target Patient Pool of Letairis
8.7.2 Dosing
8.7.3 Market Penetration
8.7.4 Annual Cost of Therapy
8.7.5 Sales Projections of Letairis/Volibris
9 PAH Market: Appendix
9.1 Market Definitions
9.2 List of Abberiviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Number of Patients Approved to take the Drug
9.3.5 Net Penetration of Drug
9.3.6 Net Annual Dosing
9.3.7 Annual Cost of Therapy
9.3.8 Primary Research
9.3.9 Expert Panels
9.4 Drug Sales Estimates Model
9.5 Contact Us
9.6 Disclaimer
9.7 Sources

1.1 List of Tables
Table 1: PAH, Global, Major Marketed Drugs
Table 2: PAH, Global, Pipeline (PhaseIII)
Table 3: PAH Drugs Evolution
Table 4: Effects of Letairis/Volibris on 6-Minute Walk Distance
Table 5: Incidence of Clinical Worsening
Table 6: Adverse Events Occurring in =3% of Patients Treated with Letairis 5-10mg once Daily
Table 7: Approval History of Letairis/Volibris in PAH
Table 8: Drug Risk Benefit Score of Letairis/Volibris
Table 9: Letairis/Volibris, Annual Cost of Therapy in PAH, Global, 2010
Table 10: Letairis/Volibris, Global, Sales Estimates ($m), 2007–2020
Table 11: Letairis, PAH, The US, Sales Estimates ($m), 2007–2020
Table 12: Volibris, PAH, The UK, Sales Estimates ($m), 2008–2020
Table 13: Volibris, PAH, France, Sales Estimates ($m), 2008–2020
Table 14: Volibris, PAH, Germany, Sales Estimates ($m), 2008–2020
Table 15: Volibris, PAH, Italy, Sales Estimates ($m), 2008–2020
Table 16: Volibris, PAH, Spain, Sales Estimates ($m), 2008–2020
Table 17: Volibris, PAH, Japan, Sales Estimates ($m), 2010–2020

1.2 List of Figures
Figure 1: PAH, Global, Market Size Forecasts ($bn), 2010–2020
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010
Figure 3: Drug Model Diagram of Letairis/Volibris
Figure 4: Letairis/Volibris, PAH, Global, Sales Estimates ($m), 2007–2020
Figure 5: Letairis, PAH, The US, Sales Estimates ($m), 2007–2020
Figure 6: Volibris, PAH, The UK, Sales Estimates ($m), 2008–2020
Figure 7: Volibris, PAH, France, Sales Estimates ($m), 2008–2020
Figure 8: Volibris, PAH, Germany, Sales Estimates ($m), 2008–2020
Figure 9: Volibris, PAH, Italy, Sales Estimates ($m), 2008–2020
Figure 10: Volibris, PAH, Spain, Sales Estimates ($m), 2008–2020
Figure 11: Volibris, PAH, Japan, Sales Estimates ($m), 2010–2020
Figure 12: Letairis/Volibris, PAH, Global, Sales Distribution by Country (%), 2015
Figure 13: Drug Model Diagram
Figure 14: Patients Approved for the Drug